Top

Critical Care

Published in:

Open Access 01-12-2020 | Shock | Letter

Should we use angiotensin II infusion in COVID-19-associated vasoplegic shock?

Author: Karim Bendjelid

Published in: Critical Care | Issue 1/2020

Excerpt

To the editor: …

Zangrillo A, Landoni G, Beretta L, Morselli F, Serpa Neto A, Bellomo R, COVID-BioB Study Group, Zangrillo A, et al. Angiotensin II infusion in COVID-19-associated vasodilatory shock: a case series. Crit Care. 2020;24:227. https://doi.org/10.1186/s13054-020-02928-0.CrossRefPubMedPubMedCentral

Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, Su X, Cao B. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020;395:1517–20.CrossRef

South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318:H1084–90.CrossRef

Wu Z, Hu R, Zhang C, Ren W, Yu A, Zhou X. Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients. Crit Care. 2020;24:290. https://doi.org/10.1186/s13054-020-03015-0.CrossRefPubMedPubMedCentral

Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui CC, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Among authors: Kuba K. Nature. 2005;436:112–6.CrossRef

Li W, Moore MJ, Vasilieva N, Sui J, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–4.CrossRef

Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–3.CrossRef

Busse LW, Chow JH, McCurdy MT, Khanna AK. COVID-19 and the RAAS—a potential role for angiotensin II? Crit Care. 2020;24:136–9.CrossRef

Koka V, Huang XR, Chung AC, Wang W, Truong LD, Lan HY. Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. Am J Pathol. 2008;172:1174–83.CrossRef

Title: Should we use angiotensin II infusion in COVID-19-associated vasoplegic shock?
Author: Karim Bendjelid
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Shock
Shock
SARS-CoV-2
Acute Respiratory Distress-Syndrome
COVID-19
Published in: Critical Care / Issue 1/2020
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/s13054-020-03144-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Should we use angiotensin II infusion in COVID-19-associated vasoplegic shock?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2020

Safe patient transport for COVID-19

Biomarkers to delineate bacteremia from candidemia remain a challenging issue

Is a more aggressive COVID-19 case detection approach mitigating the burden on ICUs? Some reflections from Italy

The fluid challenge

Systematic assessment of fluid responsiveness during early septic shock resuscitation: secondary analysis of the ANDROMEDA-SHOCK trial

The causal link between hyperchloremia and acute kidney injury is yet to be conclusively established: we are not sure